Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07439250 · ClinicalTrials.gov registry record · Phase 1

A Study of Olomorasib (LY3537982) in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT07439250: Recruiting Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT07439250 is a Phase 1 study of Healthy that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 15 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07439250, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overnight stays in the research center.

Primary Outcome

PK: Area Under the Concentration Versus Time Curve (AUC) of olomorasib

Conditions Studied

Healthy

Interventions

  • DRUG Fluconazole
  • DRUG Olomorasib

Study Locations (1)

Florida

  • Fortrea Clinical Research Unit - Daytona Beach - Daytona Beach

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2026-03-02
Est. Completion 2026-04
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What NCT07439250 shows while recruiting

NCT07439250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Fluconazole is the first listed.

NCT07439250 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07439250 about?

NCT07439250 is a clinical study titled "A Study of Olomorasib (LY3537982) in Healthy Participants". The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overn...

What is the current status of trial NCT07439250?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-03-02. Estimated completion is 2026-04.

What conditions does trial NCT07439250 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT07439250?

The interventions under investigation include: Fluconazole (DRUG), Olomorasib (DRUG).

Who is sponsoring clinical trial NCT07439250?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07439250 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07439250's enrollment target sits among peer trials

15 955th of 1090 higher than 118 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07439250

Source: ClinicalTrials.gov NCT07439250, the US trial registry maintained by the National Library of Medicine. NCT07439250 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.